If you’re someone with a big chunk of money in the stock market right now, you’re probably pretty happy with the state of ...

Retirement accounts clawed back much of what was lost while highlighting how deeply policy shifts can hit workers’ savings.

Investing.com -- Insmed Inc (NASDAQ:INSM) stock tumbled 17.2% in after-hours trading Wednesday after the biopharmaceutical company announced its Phase 2b BiRCh study of brensocatib in patients with ...

ADHD medications work like sleep, not attention boosters, massive brain study reveals. For some kids, focus problems may be ...

Investing.com -- Arcus Biosciences (NYSE:RCUS) stock fell 8% after the clinical-stage biopharmaceutical company announced it would discontinue its Phase 3 STAR-221 cancer study due to futility.

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 12, Eli Lilly and ...

Agios upgraded after FDA approval of Aqvesme for thalassemia. Explore AGIO’s financial outlook, upside potential, and future ...

Households that start taking blockbuster GLP-1 appetite suppressants like Ozempic and Wegovy slash food spending within ...

The trial narrowly missed its primary endpoint; however, Oppenheimer highlighted that omitting four patients with eligibility ...

The Motilal Oswal study reveals a cumulative wealth loss of ₹66,600 crore among the top 10 companies, with consumer sectors heavily impacted. Vodafone Idea and Rajesh Exports are notable wealth ...

Vor Biopharma has done well to continue to advance its very own global phase 3 study using its dual BAFF/APRIL inhibitor ...

Financial markets are often seen as chaotic and unpredictable. Every day, traders around the world buy shares and sell assets ...